outstandin result key word

Imugene Managing Director Dr Warwick Lamb said, “the decision to move our laboratory
research work from contract facilities to our own laboratory has paid off with this
outstanding result. Imugene’s chief scientific officer Dr Mike Sheppard has, in a very
short time successfully engineered the vaccine candidates for both the broiler market
and the broiler breeder and egg layer markets.
“The vaccine candidates have been thoroughly verified by a series of in-house and
external tests and are exactly what we want them to be. A pilot trial to test both
candidates in a bird flu challenge trial has been designed and negotiations are underway
to secure a trial facility and starting date.”
================================



Recent Publications on Avian Influenza support Imugene’s research
Recent publications in scientific journals in which the HA antigen has been successfully inserted into adenoviruses to create an effective vaccine support the research approach Imugene has undertaken. The vaccines in publications to date still require at least two injections and take at least 21 days to provide immunity. This results in protection for only half the average life of a broiler (meat producing) bird. These parameters severely limit the commercial viability of the vaccines to date. The adenoviruses used have all been human strains or avian strains that are classed as "replication defective" This means they are unable to multiply in the birds and therefore require higher doses. In contrast, the Imugene vaccine candidates are based on Imugene’s patented avian adenovirus that is replication competent (able to multiply after administration). This methodology has the following advantages:
1. Suitable for oral or in ovo (into the egg) administration
2. Lower dose (often 1/1000th of that required for replication
defective vectors)
3. Possibility of single dose
4. Allows differentiation of vaccinated from infected birds